PuSH - Publikationsserver des Helmholtz Zentrums München

Kellner, M. ; von Neubeck, B. ; Czogalla, B.* ; Feederle, R. ; Vick, B. ; Jeremias, I. ; Zeidler, R.

A novel anti-CD73 antibody that selectively inhibits membrane 2 CD73 shows antitumor activity and induces tumor immune escape.

Biomedicines 10:825 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
CD73 catalyzes the conversion of ATP to adenosine, which is involved in various physiological and pathological processes, including tumor immune escape. Because CD73 expression and activity are particularly high on cancer cells and contribute to the immunosuppressive properties of the tumor environment, it is considered an attractive target molecule for specific cancer therapies. In line, several studies demonstrated that CD73 inhibition has a significant antitumor effect. How-ever, complete blocking of CD73 activity can evoke autoimmune phenomena and adverse side ef-fects. We developed a CD73-specific antibody, 22E6, that specifically inhibits the enzymatic activity of membrane-tethered CD73 present in high concentrations on cancer cells and cancer cell-derived extracellular vesicles but has no inhibitory effect on soluble CD73. Inhibition of CD73 on tumor cells with 22E6 resulted in multiple effects on tumor cells in vitro, including increased apoptosis and interference with chemoresistance. Intriguingly, in a xenograft mouse model of acute lymphocytic leukemia (ALL), 22E6 treatment resulted in an initial tumor growth delay in some animals, followed by a complete loss of CD73 expression on ALL cells in all 22E6 treated animals, indicating tumor immune escape. Taken together, 22E6 shows great potential for cancer therapy, favorably in combination with other drugs.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Adenosine ; Cancer Therapy ; Cd73 ; Extracellular Vesicles ; Immune Evasion ; Therapeutic Antibody
ISSN (print) / ISBN 2227-9059
e-ISSN 2227-9059
Zeitschrift Biomedicines
Quellenangaben Band: 10, Heft: 4, Seiten: , Artikelnummer: 825 Supplement: ,
Verlag MDPI
Verlagsort Basel, Switzerland
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)
CF Monoclonal Antibodies (CF-MAB)
Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)
Förderungen Helmholtz Zentrum Munchen